Board Meeting Details

The Board Meeting commenced at 02:00 p.m. and concluded at 2:45 p.m. on 31st October, 2026.

Key Financial Figures (Amount in Lakhs)

Income Statement Highlights for Half Year Ended 30th September, 2026:

  • Revenue from Operations: ₹2,944.47 (vs. ₹1,406.46 in H1 FY26)
  • Other Income: ₹15.78
  • Total Income: ₹2,960.26
  • Total Expenses: ₹2,391.26
  • Profit Before Tax: ₹569.00 (vs. ₹291.08 in H1 FY26)
  • Total Tax Expense: ₹96.19
  • Profit for the Period: ₹472.81 (vs. ₹238.00 in H1 FY26)
  • Earnings Per Equity Share (Basic and Diluted): ₹6.53 (vs. ₹4.83 in H1 FY26)
  • Paid-up Share Capital: ₹724.00 (Face Value ₹10/share)

Balance Sheet Highlights as at 30th September, 2026:

  • Total Equity and Liabilities: ₹5,025.37
  • Shareholders' Funds: ₹4,020.13 (Share Capital: ₹724.00, Reserves and Surplus: ₹3,296.13)
  • Total Assets: ₹5,025.37
  • Current Assets: ₹4,182.22 (including Inventories: ₹1,154.66, Trade Receivables: ₹1,325.05)
  • Non-Current Assets: ₹843.15 (including Property, Plant & Equipment: ₹491.57)

Cash Flow Statement for Half Year Ended 30th September, 2026:

  • Net Cash from Operating Activities: ₹113.82
  • Net Cash Used in Investing Activities: (₹568.22)
  • Net Cash from Financing Activities: ₹341.71
  • Net Decrease in Cash and Cash Equivalents: (₹112.69)
  • Cash and Cash Equivalents at end of period: ₹14.89

IPO Proceeds Utilization

The company made an initial public offering (IPO) of 19,20,000 equity shares of face value of ₹10 each at a price of ₹129 per equity share (including share premium of ₹109 per equity share) aggregating to ₹24,76,80,000. The equity shares got listed on BSE SME Platform on 4th February, 2026.

Utilization of IPO proceeds of ₹2,476.80 lakhs as of 30th September, 2026:

  • Purchase of Machineries for Automation in existing Manufacturing unit: ₹421.66 (fully utilized)
  • Purchase of Machineries for New Manufacturing Setup: ₹803.23 (fully utilized)
  • Funding working capital requirements: ₹550.00 (fully utilized)
  • General corporate purposes: ₹369.04 (fully utilized)
  • IPO related Expenses: ₹332.87 (fully utilized)

Additional Notes

  • The company is mainly engaged in the business of manufacture, process, trade, sale, purchase, import, export, assemble, distribute, formulate, develop, consult, test and deal in all kinds of Drugs, Nutraceutical Wellness products and related products.
  • The financial results were reviewed by the Audit Committee and approved by the Board of Directors.
  • The limited review was conducted by VS SB & Associates, Chartered Accountants (Firm No. 121356).
  • The balance amount of IPO proceeds, if any, remains invested in short-term fixed deposits or bank balances, pending deployment for approved purposes.